FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2611210216> ?p ?o ?g. }

• W2611210216 endingPage "1715" @default.
• W2611210216 startingPage "1703" @default.
• W2611210216 abstract "Postmenopausal osteoporosis is often treated with bisphosphonates (eg, alendronate, [ALN]), but oversuppression of bone turnover by long-term bisphosphonate treatment may decrease bone tissue heterogeneity. Thus, alternate treatment strategies after long-term bisphosphonates are of great clinical interest. The objective of the current study was to determine the effect of intermittent parathyroid hormone (PTH) following 12 weeks of ALN (a bisphosphonate) treatment in 6-month-old, ovariectomized (OVX) rats on bone microarchitecture, bone remodeling dynamics, and bone mechanical properties at multiple length scales. By using in vivo μCT and 3D in vivo dynamic bone histomorphometry techniques, we demonstrated the efficacy of PTH following ALN therapy for stimulating new bone formation, and increasing trabecular thickness and bone volume fraction. In healthy bone, resorption and formation are coupled and balanced to sustain bone mass. OVX results in resorption outpacing formation, and subsequent bone loss and reduction in bone tissue modulus and tissue heterogeneity. We showed that ALN treatment effectively reduced bone resorption activity and regained the balance with bone formation, preventing additional bone loss. However, ALN treatment also resulted in significant reductions in the heterogeneity of bone tissue mineral density and tissue modulus. On the other hand, PTH treatment was able to shift the bone remodeling balance in favor of formation, with or without a prior treatment with ALN. Moreover, by altering the tissue mineralization, PTH alleviated the reduction in heterogeneity of tissue material properties induced by prolonged ALN treatment. Furthermore, switching to PTH treatment from ALN improved bone's postyield mechanical properties at both the whole bone and apparent level compared to ALN alone. The current findings suggest that intermittent PTH treatment should be considered as a viable treatment option for patients with prior treatment with bisphosphonates. © 2017 American Society for Bone and Mineral Research." @default.
• W2611210216 created "2017-05-12" @default.
• W2611210216 creator A5008484635 @default.
• W2611210216 creator A5018628074 @default.
• W2611210216 creator A5020700381 @default.
• W2611210216 creator A5037208726 @default.
• W2611210216 creator A5039680912 @default.
• W2611210216 creator A5044124597 @default.
• W2611210216 creator A5071215763 @default.
• W2611210216 creator A5071922281 @default.
• W2611210216 creator A5074929175 @default.
• W2611210216 creator A5079197655 @default.
• W2611210216 creator A5085126068 @default.
• W2611210216 date "2017-06-13" @default.
• W2611210216 modified "2023-10-15" @default.
• W2611210216 title "Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats" @default.
• W2611210216 cites W1559337502 @default.
• W2611210216 cites W1608187619 @default.
• W2611210216 cites W1874027545 @default.
• W2611210216 cites W1965930865 @default.
• W2611210216 cites W1970215274 @default.
• W2611210216 cites W1973045888 @default.
• W2611210216 cites W1981291480 @default.
• W2611210216 cites W1992142686 @default.
• W2611210216 cites W1996281846 @default.
• W2611210216 cites W2000929106 @default.
• W2611210216 cites W2013599591 @default.
• W2611210216 cites W2019076654 @default.
• W2611210216 cites W2021161524 @default.
• W2611210216 cites W2027829165 @default.
• W2611210216 cites W2031772490 @default.
• W2611210216 cites W2032208190 @default.
• W2611210216 cites W2032886398 @default.
• W2611210216 cites W2040944157 @default.
• W2611210216 cites W2041578222 @default.
• W2611210216 cites W2041598849 @default.
• W2611210216 cites W2043028345 @default.
• W2611210216 cites W2050318500 @default.
• W2611210216 cites W2060298455 @default.
• W2611210216 cites W2065308524 @default.
• W2611210216 cites W2068167547 @default.
• W2611210216 cites W2069596999 @default.
• W2611210216 cites W2069860666 @default.
• W2611210216 cites W2071234903 @default.
• W2611210216 cites W2078391984 @default.
• W2611210216 cites W2080112705 @default.
• W2611210216 cites W2085668222 @default.
• W2611210216 cites W2086933933 @default.
• W2611210216 cites W2087378917 @default.
• W2611210216 cites W2088814397 @default.
• W2611210216 cites W2099028287 @default.
• W2611210216 cites W2103502150 @default.
• W2611210216 cites W2112357770 @default.
• W2611210216 cites W2113162921 @default.
• W2611210216 cites W2121072828 @default.
• W2611210216 cites W2130916789 @default.
• W2611210216 cites W2136906270 @default.
• W2611210216 cites W2139785110 @default.
• W2611210216 cites W2142289438 @default.
• W2611210216 cites W2146701571 @default.
• W2611210216 cites W2147123976 @default.
• W2611210216 cites W2150070711 @default.
• W2611210216 cites W2151141151 @default.
• W2611210216 cites W2151147342 @default.
• W2611210216 cites W2152017463 @default.
• W2611210216 cites W2154633167 @default.
• W2611210216 cites W2169251377 @default.
• W2611210216 cites W2293642791 @default.
• W2611210216 cites W2307020139 @default.
• W2611210216 cites W2624963411 @default.
• W2611210216 doi "https://doi.org/10.1002/jbmr.3165" @default.
• W2611210216 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5550334" @default.
• W2611210216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28467646" @default.
• W2611210216 hasPublicationYear "2017" @default.
• W2611210216 type Work @default.
• W2611210216 sameAs 2611210216 @default.
• W2611210216 citedByCount "9" @default.
• W2611210216 countsByYear W26112102162018 @default.
• W2611210216 countsByYear W26112102162020 @default.
• W2611210216 countsByYear W26112102162021 @default.
• W2611210216 countsByYear W26112102162022 @default.
• W2611210216 countsByYear W26112102162023 @default.
• W2611210216 crossrefType "journal-article" @default.
• W2611210216 hasAuthorship W2611210216A5008484635 @default.
• W2611210216 hasAuthorship W2611210216A5018628074 @default.
• W2611210216 hasAuthorship W2611210216A5020700381 @default.
• W2611210216 hasAuthorship W2611210216A5037208726 @default.
• W2611210216 hasAuthorship W2611210216A5039680912 @default.
• W2611210216 hasAuthorship W2611210216A5044124597 @default.
• W2611210216 hasAuthorship W2611210216A5071215763 @default.
• W2611210216 hasAuthorship W2611210216A5071922281 @default.
• W2611210216 hasAuthorship W2611210216A5074929175 @default.
• W2611210216 hasAuthorship W2611210216A5079197655 @default.
• W2611210216 hasAuthorship W2611210216A5085126068 @default.
• W2611210216 hasBestOaLocation W26112102161 @default.
• W2611210216 hasConcept C105702510 @default.
• W2611210216 hasConcept C126322002 @default.
• W2611210216 hasConcept C134018914 @default.

• next